



Zymeworks to Present at UBS Global Healthcare Conference

May 12, 2017

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. ("Zymeworks") (NYSE:ZYME; TSX:ZYME) a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today announced it will present at the 2017 UBS Global Healthcare Conference.

Conference Details:

Event: UBS Global Healthcare Conference
Date/Time: May 23, 2017 at 11:30 a.m. EDT
Location: New York, NY

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. Zymeworks' suite of complementary therapeutic platforms and its fully-integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates. Zymeworks' lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in an adaptive Phase 1 clinical trial. Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. In addition to Zymeworks' wholly-owned pipeline, its therapeutic platforms have been further leveraged through multiple strategic partnerships with global biopharmaceutical companies.

View source version on [businesswire.com](http://www.businesswire.com/news/home/20170512005140/en/): <http://www.businesswire.com/news/home/20170512005140/en/>

Zymeworks Inc.
Investor Inquiries:
David Matousek, 604-678-1388
Senior Manager, Investor Relations & Corporate Communications
[\[email protected\]](#)

Source: Zymeworks Inc.